New Triple-Drug attack shows promise against tough blood cancer
NCT ID NCT07486479
First seen Mar 28, 2026 · Last updated May 23, 2026 · Updated 10 times
Summary
This study tests a new combination of three drugs (venetoclax, azacitidine, and mitoxantrone liposome) against the standard two-drug therapy for adults newly diagnosed with acute myeloid leukemia (AML). About 204 participants aged 18 to 65 will be randomly assigned to receive either the new or standard treatment. The main goal is to see if the new combo leads to more complete remissions and better clearance of hidden cancer cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of Nantong University
Nantong, Jiangsu, 226001, China
-
Affiliated Hospital of Nantong University
Nantong, Jiangsu, 226001, China
Contact
Contact
-
Changzhou First People's Hospital
Changzhou, Jiangsu, 213003, China
Contact
-
Huai'an Second People's Hospital
Huai'an, Jiangsu, 223002, China
Contact
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China
Contact
Contact
-
Jiangsu Province Hospital of Chinese Medicine
Nanjing, Jiangsu, 210029, China
Contact
-
Jingjiang People's Hospital
Jingjiang, Jiangsu, 214500, China
Contact
-
Northern Jiangsu People's Hospital
Yangzhou, Jiangsu, 225001, China
-
Renmin Hospital of Wuhan University
Wuhan, Hubei, China
Contact
-
Shandong First Medical University Affiliated Tumor Hospital
Jinan, Shandong, China
Contact
-
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, 230022, China
Contact
-
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, 41003, China
Contact
-
The First Affiliated Hospital of Ningbo University
Ningbo, Zhejiang, 315010, China
Contact
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215006, China
Contact
Contact
-
The First People's Hospital Of Lianyungang
Lianyungang, Jiangsu, 222002, China
Contact
-
The Second People's Hospital of Lianyungang
Lianyungang, Jiangsu, 222006, China
Contact
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430030, China
Contact
-
Wuxi People's Hospital
Wuxi, Jiangsu, 214023, China
Contact
-
YanCheng NO.1 People's Hospital
Yancheng, Jiangsu, 224006, China
Contact
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
Contact
Conditions
Explore the condition pages connected to this study.